Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden.

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

Multichain biotherapeutics continue to be a promising therapeutic modality. “These therapeutic recombinant proteins are typically assembled from at least three distinct polypeptide chains,” says ...

mRNA vaccine research will be stripped of $500 million in funding from the U.S. Department of Health and Human Services (HHS). The agency listed 22 projects that will be affected, many of which are ...

When Turnstone Biologics was founded, its team had high hopes for the California-based biotech to “lead the fight against solid tumors.” At first, it was keen on developing oncolytic viruses, which ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is expected to exceed $850 billion worldwide by 2032. Driving forces behind this ...

Having just enough of a fatty substance (lipid) called cholesterol in your body is important for bodily functions, but having too much of it, known as high cholesterol, can increase your risk of ...